Program
Human Papillomavirus Recombinant Vaccine nonavalent
Also written as “V503”, “9vHPV Vaccine” and “9vHPV vaccine”.
Its studies are mostly in Papillomavirus Infections · Condylomata Acuminata · Uterine Cervical Neoplasms · Papilloma · Dengue, led by 5 companies.
Drug pageHuman Papillomavirus Recombinant Vaccine nonavalent: every studyMany companies study it; this page follows only the 25 they lead. All 74 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 207 open or running | phase 3since Jul 21, 2009 | Jul 21, 2009 | Jan 15, 2027phase 3 · NCT04199689 |
| Shanghai Bovax Biotechnologyits history only | 21 open or running | phase 3since Jun 8, 2020 | Jun 8, 2020 | none ahead |
| Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chairits history only | 11 open or running | early phase 1since Apr 28, 2025 | Apr 28, 2025 | none ahead |
| Takedaits history only | 10 open or running | phase 3since Mar 16, 2020 | Mar 16, 2020 | none ahead |
| Xiamen Innovax Biotechits history only | 11 open or running | phase 4since Jun 16, 2026 | Jun 16, 2026 | Feb 28, 2027phase 4 · NCT07668271 |
Also a collaborator on its studies: Chongqing Bovax Biopharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Jul 21, 2009.
- Jun 21, 2019Phase 3 study in Papillomavirus InfectionsMerck · NCT03998254 · 6,000 enrolled · China
- Dec 12, 2019Phase 3 study in Papillomavirus InfectionsMerck · NCT04199689 · 6,033 enrolled · United States, Belgium, Brazil and more
- Mar 16, 2020Takeda’s first study: phase 3 study in DengueNew to TakedaTakeda · NCT04313244 · 614 enrolled · Thailand
- Jun 8, 2020Shanghai Bovax Biotechnology’s first study: phase 3 study in Uterine Cervical NeoplasmsNew to Shanghai Bovax BiotechnologyShanghai Bovax Biotechnology · NCT04425291 · 1,680 enrolled · China
- Nov 5, 2020Phase 3 study in Condylomata AcuminataMerck · NCT04635423 · 1,059 enrolled · Japan
- Jan 12, 2021Phase 3 study in Papillomavirus InfectionsMerck · NCT04708041 · 700 enrolled · United States, Colombia, Mexico and more
- Feb 23, 2021Phase 3 study in Papillomavirus InfectionsMerck · NCT04772534 · 314 enrolled · Japan
- May 17, 2021Phase 3 study in Papillomavirus InfectionsShanghai Bovax Biotechnology · NCT04895020 · 1,200 planned · China
- Nov 10, 2021Phase 3 study in Papillomavirus InfectionsMerck · NCT05119855 · 165 enrolled · United States
- Mar 8, 20222 phase 3 studiesMerck · NCT05285826, NCT05314023
- Jun 28, 2022Phase 3 study in Papillomavirus InfectionsMerck · NCT05450705 · 1,500 enrolled · China
- Apr 28, 2025Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair’s first study: early phase 1 study in Papillomavirus InfectionsNew to Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · NCT06959563 · 20 enrolled · United States
- Jun 16, 2026Xiamen Innovax Biotech’s first study: phase 4 study in Infection by Human Papilloma VirusNew to Xiamen Innovax BiotechXiamen Innovax Biotech · NCT07668271 · 720 planned · China
- Aug 21, 2026Phase 3 study in Papillomavirus InfectionsMerck · NCT07785843 · 930 planned · China
Ahead
- Jan 15, 2027Primary completion: phase 3 study in Papillomavirus InfectionsMerck · NCT04199689
- Feb 28, 2027Primary completion: phase 4 study in Infection by Human Papilloma VirusXiamen Innovax Biotech · NCT07668271
- Dec 18, 2027Primary completion: phase 3 study in Papillomavirus InfectionsMerck · NCT07785843
- Mar 31, 2028Primary completion: phase 3 study in Papillomavirus InfectionsMerck · NCT03998254
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07785843Papillomavirus Infections · China | 3 | Recruiting | Merck | Dec 18, 2027 | 930 |
| NCT07668271Infection by Human Papilloma Virus · China | 4 | Recruiting | Xiamen Innovax Biotech | Feb 28, 2027 | 720 |
| NCT06959563Papillomavirus Infections · United States | Early 1 | Active, not recruiting | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Oct 18, 2026 | 20 |
| NCT05450705Papillomavirus Infections · China | 3 | Active, not recruiting | Merck | Aug 3, 2029 | 1,500 |
| NCT05314023Condylomata Acuminata · China | 3 | Active, not recruiting | Merck | Feb 19, 2029 | 1,590 |
| NCT05285826Papillomavirus Infections · China | 3 | Active, not recruiting | Merck | May 25, 2029 | 8,100 |
| NCT05119855Papillomavirus Infections · United States | 3 | Completed | Merck | Dec 12, 2023 | 165 |
| NCT04895020Papillomavirus Infections · China | 3 | Recruiting | Shanghai Bovax Biotechnology | Jan 13, 2023 | 1,200 |
| NCT04772534Papillomavirus Infections · Japan | 3 | Completed | Merck | Apr 6, 2024 | 314 |
| NCT04708041Papillomavirus Infections · United States, Colombia, Mexico and more | 3 | Active, not recruiting | Merck | Oct 23, 2029 | 700 |
| NCT04635423Condylomata Acuminata · Japan | 3 | Completed | Merck | Dec 31, 2023 | 1,059 |
| NCT04425291Uterine Cervical Neoplasms · China | 3 | Completed | Shanghai Bovax Biotechnology | Sep 6, 2021 | 1,680 |
| NCT04313244Dengue · Thailand | 3 | Completed | Takeda | Feb 21, 2022 | 614 |
| NCT04199689Papillomavirus Infections · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Merck | Jan 15, 2027 | 6,033 |
| NCT03998254Papillomavirus Infections · China | 3 | Active, not recruiting | Merck | Mar 31, 2028 | 6,000 |
| NCT03903562Papillomavirus Infections · China | 3 | Completed | Merck | Feb 28, 2025 | 1,990 |
| NCT03546842Papillomavirus Infections · Vietnam | 3 | Completed | Merck | Jan 29, 2019 | 201 |
| NCT03158220Uterine Cervical Neoplasms · Austria, Belgium, Finland and more | 3 | Completed | Merck | Nov 19, 2018 | 1,212 |
| NCT02114385Papillomavirus Infections · Belgium, Germany, Netherlands | 3 | Completed | Merck | Apr 22, 2015 | 500 |
| NCT01984697Papillomavirus Infections | 3 | Completed | Merck | Jun 19, 2015 | 1,518 |
| NCT01651949Condylomata Acuminata | 3 | Completed | Merck | Aug 4, 2014 | 2,520 |
| NCT01304498Human Papillomavirus | 3 | Completed | Merck | Dec 20, 2011 | 600 |
| NCT01254643Papillomavirus Infections | 3 | Completed | Merck | Aug 10, 2013 | 100 |
| NCT01047345Uterine Cervical Neoplasms | 3 | Completed | Merck | Jun 10, 2011 | 924 |
| NCT00943722Uterine Cervical Neoplasms | 3 | Completed | Merck | Apr 30, 2011 | 3,074 |
How it is read
Names in the registry
- “V503”, 10 entries
- “9vHPV Vaccine”, 5 entries
- “9vHPV vaccine”, 5 entries
- “9-valent HPV vaccine (Cecolin 9)”, 1 entry
- “9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use”, 1 entry
Conditions, from the studies’ own filings
- Papillomavirus Infections, 13 studies
- Condylomata Acuminata, 5 studies
- Uterine Cervical Neoplasms, 4 studies
- Papilloma, 1 study
- Dengue, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.